Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure

REFERENCES

• Shima M, Seino Y, Torikai S, Imai M. Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments. Life Sci. 1988;43:357–363.
   PubMedGoogle Scholar
• Stephenson SL, Kenny AJ. The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243:183–187.
   PubMed Web of Science ®Google Scholar
• Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: Indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor. Clin Sci. 1992;82:619–623.
   PubMed Web of Science ®Google Scholar
• Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JCJr.. Neutral endopeptidase inhibition potentiates natriuretic actions of adrenomedullin. Am J Physiol. 1998;275:F410–F414.
   PubMed Web of Science ®Google Scholar
• Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5:769–776.
   PubMed Web of Science ®Google Scholar
• Richards AM, Wittert G, Crozier IG, Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407–416.
   PubMed Web of Science ®Google Scholar
• Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525–1532.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Vasopeptidase inhibition. A double-edged sword? Hypertension. 2003;41:383–389.
   PubMed Web of Science ®Google Scholar
• Fl Martin, Stevens TL, Cataliotti A, Natriuretic and anti aldosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney Int. 2005;67:1723–1730.
   Google Scholar
• Benigni A, Zoja C, Zatelli C, Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int. 2004;66:1959–1965.
   PubMed Web of Science ®Google Scholar
• Marumo T, Nakaki T, Hishikawa K, Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3’,5’-monophosphate elevation in vascular smooth muscle cells. Endocrinology. 1995;136:2135–2142.
   PubMed Web of Science ®Google Scholar
• Burnett JCJr.. Vasopeptidase inhibition: A new concept in blood pressure management. J Hypertens. 1999;17:S37–S43.
   Google Scholar
• Burrell LM, Farina NK, Balding LC, Johnston CJ. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension. 2000;36:1105–1111.
   PubMed Web of Science ®Google Scholar
• Grantham JA, Schirger JA, Wennberg PW, Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. Circulation. 2000;101:1976–1981.
   PubMed Web of Science ®Google Scholar
• Ando S, Rahman MA, Butler JC, Senn BL, Floras JC. Comparison of candoxatril and atrilal natriuretic factor in healthy men: Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26:1160–1166.
   PubMed Web of Science ®Google Scholar
• Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001;60:715–721.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601–1608.
   PubMed Web of Science ®Google Scholar
• Karam H, Bruneval P, Clozel JP, Loffler BM, Bariety J, Clozel M. Role of endothelin in acute renal failure due to rhabdomyolysis in rats. J Pharmacol Exp Ther. 1995;274:481–486.
   PubMed Web of Science ®Google Scholar
• Mandal AK, Davis JBJr, Bell RD, Miller JM. Myoglobinuria exacerbates ischemic renal damage in the dog. Nephron. 1989;53:261–267.
   PubMed Web of Science ®Google Scholar
• Newaz MA, Oyekan AO. Vascular responses to endothelin-1, angiotensin II and U46619 in glycerol-induced acute renal failure. J Cardiovasc Pharmacol. 2001;38:569–577.
   PubMedGoogle Scholar
• Yousefipour Z, Ao Oyekan, Newaz MA. Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene. Ren Fail. 2007;29:903–910.
   PubMed Web of Science ®Google Scholar
• Lipkin GW, Dawnay AB, Harwood SM, Cattell WR, Raine AE. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. Kidney Int. 1997;52:792–801.
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K, Burrell LM, Kanazawa M, Casley D, Jackson B, Johnson CI. Effects of neutral endopeptidase inhibition I the rat remnant kidney model. Kidney Blood Press Res. 1998;21:419–424.
   Google Scholar
• Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol. 1998;32:87–95.
   Google Scholar
• Newaz MA, Yousefipour Z, Hercule H, Truong L, Oyekan AO. Chronic endopeptidase inhibition in DOCA-salt hypertension: Mechanism of cardiovascular protection. Clin Exp Hypertens. 2003;25:335–347.
   PubMed Web of Science ®Google Scholar
• Rademaker MT, Fitzpatrick MA, Charles CJ, Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure. J Cardiovasc Pharmacol. 1996;27:439–446.
   Google Scholar
• Mitsutomi N, Akashi C, Odagiri J, Matsumura Y. Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells. Eur J Pharmacol. 1999;364:65–73.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kuroda T, Ikeda M, Hata S, Fujimoto M. Potential contribution of endothelin to renal abnormalities in glycerol-induced acute renal failure in rats. J Pharmacol Exp Ther. 1998;286:977–983.
   PubMed Web of Science ®Google Scholar
• Hu RM, Levin ER, Pedram A, Frank HJ. Atrial natriuretic peptide inhibits the production ad secretion of endothelin from cultured endothelial cells: Mediation through the C receptor. J Biol Chem. 1992;267:17384–17389.
   PubMed Web of Science ®Google Scholar
• Nambi P, Pullen M, Wu HL, Prabhakar U, Hersh L, Gellai M. Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: Possible mechanism for ischemia-induced acute renal failure in rats? Mol Cell Biochem. 1999;197:53–59.
   Google Scholar
• Yanagisawa H, Nodera M, Umemori Y, Role of angiotensin II, endothelin-1, and nitric oxide in HgCl2-induced acute renal failure. Toxicol Appl Pharmacol. 1998;152:315–326.
   PubMed Web of Science ®Google Scholar
• Richards AM, Wittert G, Espiner EA, Yandle TG, Ikram H, Frampton C. Effects of inhibition of endopeptidase 24.11 on response to angiotensin II inhuman volunteers. Circ Res. 1992;71:1501–1507.
   PubMed Web of Science ®Google Scholar
• Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanism of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest. 2003;33:769–778.
   Web of Science ®Google Scholar
• Oliveira-Souza M, Malnic G, Mello-Aires M. Atrial natriuretic peptide impairs the stimulatory effect of angiotensinII on H+-ATPase. Kidney Int. 2002;62:1693–1699.
   Google Scholar
• Ito T, Yoshimura M, Nakamura S, Inhibitory effect of natriuretic peptide on aldosterone synthase gene expresión in cultured neonatal rat cardiocytes. Circulation. 2003;107:807–810.
   PubMed Web of Science ®Google Scholar
• Iwanami J, Mogi M, Iwai M, Horiuchi M. Inhibition of the rennin–angiotensin system and target organ protection. Hypertens Res. 2009;32:229–237.
   PubMed Web of Science ®Google Scholar